Towards personalised management of CLL? Ibrut... - CLL Support

CLL Support

23,253 members39,949 posts

Towards personalised management of CLL? Ibrutinib study reveals new way to gauge patients’ response to treatment

bennevisplace profile image
6 Replies

Excerpts from genengnews.com/topics/omics...

***

Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has remarkable efficacy in most patients with CLL. It is becoming the standard of care for most patients requiring treatment due to its clinical efficacy and mostly tolerable side effects. However, it does not cure the disease, and patients must undergo prolonged periods of treatment.

According to Bock’s team at CeMM, CLL cells and other immune cells that respond to Ibrutinib manifest distinctive epigenetic and transcriptional patterns. These patterns predict how swiftly the treatment is having an effect on the CLL cells and how long it takes for the disease to respond in each individual patient.

In previous studies, scientists had investigated only specific aspects of the molecular response to ibrutinib, focusing largely on genetic drug resistance or the transcriptome response of cancer cells. In the current study, CeMM researchers tried a new, more comprehensive approach. They conducted a genome-scale, time-resolved analysis of the regulatory response to this drug in primary patient samples.

The scientists simultaneously monitored the activity, regulation, and expression of the CLL cells and other cell types of the immune system. Importantly, they performed this analysis at eight predefined time points during the ibrutinib therapy, following seven individual patients over a standardized 240-day period after the start of the treatment.

After the CeMM team amassed a dataset, they put it through integrative bioinformatic analysis to generate one of the first high-resolution, multi-omics time series of the molecular response to targeted therapy in cancer patients. This work, the CeMM team asserts, establishes a broadly applicable approach for analyzing drug-induced regulatory programs, identifying molecular response markers for targeted therapy.

These results will help develop personalized strategies for managing CLL as a chronic disease, which is particularly relevant for CLL as a disease of the elderly. Also, they will help stratify patients into fast and slow responders based on characteristic molecular markers and open new directions for the development of ibrutinib-based combination therapies for CLL.

***

The CeMM study is published in Nature nature.com/articles/s41467-...

Written by
bennevisplace profile image
bennevisplace
To view profiles and participate in discussions please or .
Read more about...
6 Replies
bennevisplace profile image
bennevisplace

If you're like me you'll be thinking " most of this is over my head". But it's the way science goes these days - collect more data and do more sophisticated analysis, enabled by massive computing power, to generate answers (sometimes answers to questions you hadn't even thought of).

The Vienna team's forensic "single cell multi-omics" approach does seem to elucidate what happens over time, when you pitch a drug against a CLL cell: events at the molecular level follow the same course but at a speed particular to the individual patient.

In this talk youtube.com/watch?v=ZwaX_u-... (13:30-20:00 mins and 37:00 mins) we get a glimpse of the potential in this technique to improve treatment decisions, i.e. which combination of targeted drugs would a particular patient likely respond to best.

BeckyLUSA profile image
BeckyLUSA

Thanks for posting. An interesting read (actually, I only skimmed it) but unfortunately a little above my pay grade. It does appear to say though, that our CLL response to Ibrutinib is very much an individual thing...like most everything about CLL!

bennevisplace profile image
bennevisplace in reply toBeckyLUSA

Yes, and not just to Ibrutinib. I guess the hope is that this technique ultimately will be able to explain why patients with the same CLL genetics respond differently to the same drug. And better inform treatment choices.

BeckyLUSA profile image
BeckyLUSA in reply tobennevisplace

Yes!

Smakwater profile image
Smakwater

Fascinating bennevisplace,

Articles like this and the video post always remind me of the people I have met who say things like "I'm bored".

The more information that I consume, the smaller I feel.

But, never bored.

JM

bennevisplace profile image
bennevisplace

I agree with you Smakwater. Cutting edge stuff like this is a workout for the old grey matter. The unfamiliarity is challenging but at the same time stimulating.

Not what you're looking for?

You may also like...

Clinical trial results & reviews of new treatments for CLL written in easy to understand terms

Anyone interested in reading a weekly update of the latest breaking news for CLL may want to sign...
lankisterguy profile image
Volunteer

Use of MRD Status Following Obinutuzumab/Ibrutinib to Guide Subsequent Intensification of Therapy in CLL

August 6, 2019 In this 2-part, single-arm, open-label, multicenter trial (Clinical Trials.gov...
Jm954 profile image
Administrator

Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab

For more than a year we have been reminding each other that even if we don't produce antibodies in...

Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia ( CLL ) - Pseudo Richters

Several of us have reported our CLL symptoms have come roaring back after discontinuing...
AussieNeil profile image
Partner

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with CLL

This is an abstract from the Lancet article. There's a fair bit of detail missing regarding the...
Jm954 profile image
Administrator